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SUMMARY 
 
Background. Chronic diarrhoea is a common unpleasant concomitant of gastrointestinal 
disorders, such as inflammatory bowel diseases (IBDs) or bile acid malabsorption (BAM). Its 
exact pathomechanism is still not completely understood, thus, its successful management is a 
great challenge for clinicians. Recent animal and cell-culture studies underline the crucial role 
of colonic epithelial ion transporters in the development of bile-induced diarrhoea, but there 
are just a few human data from the last century available about the influence of bile acids on 
human colonic ion-transport mechanisms. The exact treatment of IBD represents another 
unsolved problem. Nowadays biological therapy with anti-tumour necrosis factor alpha (TNF-
α)-agents opened new perspectives in the fight against IBD. However, beside the promising 
results, the loss of response, the presence of anti-drug-antibodies, low drug serum 
concentrations, hypersensitivity and allergic reactions during the administration of anti-TNF-α 
are proved to be predisposing factors for therapeutic failure. Thus, therapeutic drug 
monitoring may be a useful opportunity in order to optimise the treatment of IBD-patients.  
Moreover, IBD-patients on immunosuppressive therapy are at increased risk for infectious 
diseases, thus influenza vaccination is strongly recommended. Our aims were to investigate 
the effects of bile acids on the ion-transporter activities (namely Na+/H+ exchangers [NHE1-
3], and  Cl-/HCO3--exchanger CBE) of human colonic epithelial cells and to characterise the 
cellular pathomechanism of bile-induced diarrhoea. In the second part of the study, we aimed 
to assess tumor necrosis factor-a (TNF-a), infliximab (IFX) concentrations, and antibodies 
against IFX molecules in patients with inflammatory bowel disease (IBD) who develop loss 
of response, side effects, or allergic reaction during anti TNF-a therapy. We also evaluate the 
antibody and cell-mediated immune response to the split and whole virion influenza vaccine 
in patients with IBD treated with anti-TNF-α and/or immunosuppressive therapy. However, 
immunosuppressive and biological therapies seem to influence the immune response to 
vaccinations.  Materials and methods. In the first part of our study, patients with negative 
colonoscopic finding were involved. They were divided into three groups. The first group 
contained patients having diarrhoea after ileum-resection/cholecystectomy (Diarrhoea). In the 
second group ileum-resected/cholecystectomised patients were involved who did not develop 
diarrhoea (NON-Diarrhoea). The control group included patients without any surgical 
Number of full publications:    5 (3 first author) 
Cumulative impact factor:    10.268 
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intervention in the gastrointestinal tract. Primary colonic crypts were isolated from human 
biopsy samples. The functional characteristics of NHE1-3 and CBE, intracellular Ca2+ 
concentration ([Ca2+]i), ATP level (ATPi) and mitochondrial transmembrane potential ((∆ψ)m) 
were determined using fluorescence technique. The morphology of the intracellular organelles 
was investigated with transmission electronmicroscopy. In the second part of the study, 67 
IBD-patients, receiving the anti-TNF-α agent infliximab (IFX), were enrolled and categorized 
into two groups. Blood samples of 36 patients with loss of response, side effects, or 
hypersensitivity to IFX therapy (Group I) and 31 patients in complete clinical remission 
(Group Ⅱ) selected as a control group were collected. Enzyme-linked immunosorbent assay 
(ELISA) was applied to determine the serum levels of TNF-α, IFX trough levels, and anti-
IFX-antibody (ATI). We examined the correlation between loss of response, the development 
of side effects or hypersensitivity, and serum TNF-α, IFX trough levels, and ATI 
concentrations. In an additional part of our study, 156 immunocompromised influenza-
vaccinated IBD-patients and 53 non-vaccinated patients (control group) were involved. Split 
virion vaccine and whole virion vaccine were used. Serum samples were obtained pre- and 
postimmunisation. TNF-α, interferon-γ (IFN-γ) and interleukin-2 (IL-2) serum levels were 
measured with ELISA. Results. In vitro measurement of colonic epithelial ion transporter 
activities revealed impaired NHE and CBE activities in cholecystectomised/ileum-resected 
patients suffering from diarrhoea, compared to control patients. Acute treatment of colonic 
crypts with 0.3 mM chenodeoxycholate (CDC) caused dose-dependent intracellular acidosis; 
moreover, the activities of acid/base transporters (NHE and CBE) were strongly impaired. 
This concentration of CDC did not cause morphological changes of the intracellular 
organelles of colonic epithelial cells, although significantly reduced the ATPi, decreased 
(∆ψ)m and caused sustained elevation of [Ca2+]i. We also showed that CDC induced Ca2+-
release from the endoplasmic reticulum and extracellular Ca2+-influx contributing to the 
[Ca2+]i-elevation. The CDC-induced inhibition of NHE activities was ATP-dependent, 
whereas the inhibition of CBE activity was mediated by the sustained [Ca2+]i-elevation. We 
did not observe any inhibitory effect on the functions of ion transporters in case of the 
administration of a conjugated bile acid. In IBD-patients, receiving IFX-therapy, serum TNF-
α level was shown to be correlated with the presence of ATI; ATI positivity was significantly 
correlated with low trough levels of IFX. ATIs were detected in 25% of IBD patients with 
loss of response, side effects, or hypersensitivity, however no association was revealed 
between these patients and antibody positivity or lower serum IFX levels. Previous use of IFX 
correlated with the development of ATI, although concomitant immunosuppression did not 
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have any impact on them. Neither TNF-α, nor INF-γ levels changed significantly after 
influenza vaccination; however, a significant decrease was observed in the level of IL-2 after 
vaccination with split vs. whole virion vaccine. Discussion. Our results suggest that bile acids 
inhibit the function of human colonic epithelial ion transporters via cellular energy breakdown 
and Ca2+-overload, which can reduce fluid and electrolyte absorption in the colon and 
promote the development of diarrhoea. Furthermore, on the basis of our study, we propose 
that the simultaneous measurement of serum TNF-α level, serum anti TNF-α concentration, 
and antibodies against anti TNF-α may further help to optimize the therapy in critical 
situations. IBD-patients on immunosuppressive therapy are recommended to be immunised 
with influenza-vaccines and measuring the cytokine-responses in patients treated with 
immunosuppressants may help to determine the efficacy of influenza vaccination. 
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I. INTRODUCTION 
1. The role of human colonic epithelial ion transporters in bile-acid induced diarrhoea 
The colon plays a fundamental role in the maintenance of the water balance of the 
body by absorbing 1.5 to 1.9 liters of electrolyte-rich fluid daily, leaving just 0.1 to 0.5 liters 
to lose with the stool. The adequate activity of ion transporters localized on the apical and 
basolateral membrane of polarised epithelial cells is essential to keep the precise balance 
between absorption and secretion. The critical role of Na+/H+-exchangers (NHEs) in this 
process is well-known such as their involvement in intracellular pH (pHi) and cell volume 
regulation. The functionally coupled NHE3 and Cl-/HCO3--exchanger (CBE) downregulated 
in adenoma (DRA) are most probably responsible for the majority of electroneutral NaCl 
absorption in the colon [1-3]. So far, nine different NHE isoforms (NHE1-9) have been 
identified in mammalian cells with a specific tissue and membrane distribution [4]. These are 
transmembrane proteins which replace one extracellular Na+ for one intracellular H+. NHE1 is 
constitutively expressed on the basolateral membrane of the epithelial cells. Although it does 
not play a role in the absorption of Na+, it fulfils housekeeping functions, regulating cell 
volume and pHi. The presence of NHE2 and NHE3 on the apical membrane of colonic 
epithelial cells has been confirmed [5], however, only the prominent role of NHE3 in colonic 
Na+ absorption has been demonstrated by previous studies. The occurrence of diarrhoea in 
NHE3 knockout mice further supports the idea that this is the dominant NHE isoform 
responsible for Na+ uptake in the intestine [6-8]. Together with NHE3, the Cl-/HCO3- 
exchanger DRA, a member of the SLC26 gene family, maintains the absorption of NaCl in 
the colon. Despite that other anion exchangers are also found in the gastrointestinal tract 
(AE2, putative anion transporter-1 (PAT-1)), there are evidences that DRA is the most 
important mediator of electroneutral Cl- uptake in the large intestine [9]. Mutation of this 
transporter results in congenital chloride-losing diarrhoea [10], moreover, similar conditions 
develop in DRA-deficient mice [9]. Disturbances in colonic epithelial Na+ and/or Cl- transport 
have shown previously to be involved in the development of diarrhoea in ulcerative colitis 
(UC) and secretory diarrhoea [9, 11-13] because of the increased secretion and/or decreased 
reuptake of water and electrolytes. This fact further verifies the importance of the NHE3 and 
DRA in colonic electrolyte and water absorption. 
Bile acids (BAs) are natural detergents that participate in the solubilisation and 
absorption of dietary lipids. They are excreted into the small intestine, and most of them (90-
95%) are reclaimed in the distal ileum then return to the liver through the portal vein. When 
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this precisely regulated enterohepatic circulation impairs, bile acid malabsorption (BAM) 
occurs, thus BAs are allowed to enter the colon in higher concentration and can induce 
diarrhoea through unidentified mechanisms. BAM and diarrhoea are well-known clinical 
complications after ileal resection or after cholecystectomy [14-16].  According to the study 
of Smith et al. about the occurrence of BAM, the numbers are depressive. The prevalence of 
BAM is 97% in Crohn’s patients with resection, 58% of patients with gastric surgery and/or 
cholecystectomy, and in 33% of patients with unexplained, idiopathic chronic diarrhoea [17] . 
Since the diagnosis is not available everywhere, the disease is under-recognised, therefore 
managing bile-induced diarrhoea is a great challenge for gastroenterologists [18]. Further 
complicates the situation that the applicable therapy with the bile-acid sequestrant 
cholestyramine does not solve the problem in every case [19, 20]; on the other hand, a life-
long medication of the patients is not supportable. Moreover, cholestyramine treatment can 
reduce the bioavailability of co-administered drugs as well. During the past decades, it 
became more and more clear that the disturbed colonic absorptive and/or secretory functions, 
including Na+ and Cl- transport, must play a critical role in BAM associated diarrhoea. One of 
the earliest studies revealed the prosecretory and antiabsorptive actions of bile acids on the 
human colon, providing the first explanation for bile-induced diarrhoea [21]. Keely et al. also 
demonstrated electrolyte secretion in cultured colonic epithelial cells induced by bile salts 
[22], not to mention their sophisticated role in the overall regulation of ion and water 
movement in the colon [23]. In a recent study, Ao et al. revealed that the non-conjugated bile 
acid chenodeoxycholic acid (CDC) stimulates Cl- secretion in colonic epithelial cells via 
activation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel [24]. 
Notwithstanding, BAs are also recognised as hormones, regulating numerous intestinal and 
extra-intestinal processes [25] thus, can no longer be considered exclusively as a component 
of digestion. Their regulatory function and hormone-like properties exerted through either 
nuclear receptors or G-protein-coupled receptor (TGR5) [26] have been recognised in the last 
few years and been under a great interest. A number of elegant studies indicate the influence 
of TGR5 not only in the gastrointestinal tract (in colonic secretory responses [27], acute 
pancreatitis [28]) but in various other organ systems as well [29-32]. 
Nevertheless, the mechanism, by which BAs induce diarrhoea, is not fully elucidated 
yet, and there are just a few in vitro human study available about the influence of bile acids on 
colonic ion transport processes. Therefore, to understand to pathogenesis of bile-induced 
diarrhoea and the development of new therapeutical approaches are extremely necessary. 
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2. Biological therapy with the anti-tumor necrosis factor-α (TNF-α) infliximab (IFX) in the 
management of inflammatory bowel diseases (IBD)   
Crohn’s disease (CD) and ulcerative colitis (UC) are the two types of inflammatory 
bowel diseases (IBDs), defined as chronic disorders of the gastrointestinal tract. The most 
frequent symptom in IBD is the so-called exudative diarrhoea, defined as the presence of 
blood and/or pus in the bowel. Exudative diarrhoea is caused by an extensive injury of the 
mucosa as a result of inflammation or ulceration, leading to a loss of mucus, and the disability 
of the epithelium to fulfil its crucial absorptive and barrier function. However, diarrhoea in 
IBD is usually multifactorial. It is commonly exacerbated by other concomitants of IBD, such 
as bacterial overgrowth or infections. An additional BAM, being a common concomitant 
feature of IBD [33], may also participate in the constant existence of diarrhoea. Last, but not 
least, role of colonic epithelial ion transporters in the development of diarrhoea has to be 
mentioned as well. The decreased activity of NHE3 and damaged Na+ and Cl- absorptions in 
UC patients have already been demonstrated [12, 13]. Moreover, there is a recently 
discovered relationship between cytokine-mediated immune responses and disturbance of 
electroneutral sodium absorption. It is well known that the overexpression of proinflammatory 
cytokines, leading to a chronic systemic inflammation, is another characteristic of IBD, 
mainly that of CD. Interestingly, high levels of proinflammatory cytokines are linked to the 
pathogenesis of diarrhoea in IBD. It has been demonstrated both in animal studies and in 
cultured colonic epithelial cells, that TNF-α and interferon-γ (IFN-γ) downregulate mRNA 
and protein expression and repress the activities of NHE2 and NHE3, the key mediators of 
intestinal salt and water absorption [34, 35]. 
Although IBD is one of the most investigated topics and it is under the spotlight of 
numerous work groups, its pathophysiology is still not completely understood. Genetic, 
environmental and immunological factors are thought to be involved in the development of 
the disease. IBD is characterized by alternating periods of relapse and remission. In case of 
active disease, signs and symptoms beside diarrhoea may include abdominal pain and 
cramping, ulcers in the mouth, perianal fistulas, weight loss and fever. The severity and the 
causing factors are demonstrating a wild range of variety between patients. 
Proinflammatory cytokines, such as TNF-α, IFN-γ and the members of interleukin (IL) 
-family, have been directly implicated in the pathogenesis of IBD and they seem to have a 
crucial role in the control of intestinal inflammation and associated clinical symptoms. TNF-α 
is an outstanding component of the inflammatory processes. It is produced in lamina propria 
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by CD14+ macrophages, adipocytes, dendritic cells, fibroblasts and effector T-cells. Indeed, 
its concentration is elevated in the stool, mucosa, and blood of IBD patients [36]. TNF-α has 
been shown to induce various pro-inflammatory functions in the inflamed mucosa, such as 
hypervascularization and angiogenesis, it augments pro-inflammatory cytokine production by 
macrophages and T-cells, causes barrier alterations and promotes cell death of intestinal 
epithelial cells. TNF-α also promotes tissue destruction and drives T cells to be resistant to 
apoptosis [37]. The complexity of IBD makes a lot of difficulties in the treatment and an 
established standard therapy is lacking. In some of the cases, surgery is unavoidable; 
however, resection is not curative in the majority of the CD cases. Beside 5-aminosalicylic 
acid compounds, corticosteroids and immunosuppressive drugs, biological therapies are most 
commonly used therapeutic methods. Proinflammatory cytokine TNF-α is currently the key 
target for the management of different inflammatory diseases including IBD. Infliximab 
(IFX), a chimeric monoclonal anti-TNF-α-antibody, has been approved for the induction and 
maintenance of remission in both CD and UC. In the past decade, IFX provided new 
perspectives for the management of the diseases resulted in marked clinical improvement and 
macroscopic healing of the inflamed mucosa. However, loss of response, presence of 
antibodies against IFX, low drug serum concentrations, hypersensitivity and allergic reactions 
during the administration of anti-TNF-α are proved to be predisposing factors for therapeutic 
failure. Approximately 40% of patients will subsequently lose response, thus requiring dose 
intensification or drug change [38]. Dose intensification may be a solution in case of low anti-
TNF-α drug trough levels, while switching to another drug could be useful if antibodies are 
developed against the biological agents [39]. Immunogenicity (the formation of antibodies to 
the biological agents) is the major cause of loss of response and adverse reactions. Scheduled 
maintenance therapy, concomitant immunomodulators therapy, and pretreatment with high-
dose corticosteroids may help to reduce immunogenicity [40]. Many observational studies 
have linked low serum drug levels to a higher risk of the development of anti-drug-antibodies, 
and/or loss of response to biologics in IBD. In response, reactive measurement of anti-drug-
antibodies and serum drug levels using Enzyme Linked Immunosorbent Assay (ELISA), and 
appropriate adjustment of drug regimen, has been utilized in practice to optimize clinical 
outcomes [41]. Although the role of TNF-α measurement, together with antibody and drug 
serum concentration, has not previously been investigated in everyday practice, there are 
more and more studies emphasizing the importance of pharmacokinetic monitoring of IFX 
and anti-IFX-antibody (ATI) in order to prevent side-effects and to predict the clinical 
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response to IFX and endoscopic improvement. In this regard, therapeutic drug monitoring 
may help to optimise the treatment of IBD-patients. 
Although patients with IBD should not be routinely considered to have altered 
immunocompetence per se, there is currently no method of evaluating the effects of 
immunosuppression on the immune system. IBD-patients, receiving biological therapy and/or 
immunmodulators (azathioprine (AZA) or 6-mercaptopurine (6-MP)) are exposed to an 
increased hazard for infectious diseases, with an incremental elevation in the relative risk of 
opportunistic infection: three fold increased risk (OR 2.9, 95% CI 1.5–5.3) if any one 
immunomodulator was used, increasing substantially (OR 14.5, 95% CI 4.9–43) if two or 
more drugs were used concomitantly [42].  
Some of the infections occurring more frequently in IBD patients can be prevented with 
immunisation. Since influenza is one of the most common vaccine-preventable illnesses in 
adults, influenza vaccination is recommended for all IBD-patients on biological therapy 
and/or immunmodulators. Inactivated, split virion vaccine and inactivated whole virion 
vaccine are applied in order to precede influenza. The experimental use of the whole virion 
vaccine, which is the first inactivated vaccine formulation, dates back to the 1940s. Split 
virion is derived by disrupting whole virus particles with detergents and is thus less 
immunogenic than whole virion vaccines [43]. Whole virion vaccine is administered 
intramuscularly; split virion vaccine is administered intradermally. The types of 
immunosuppressive and biological therapies seem to affect the immune response to 
vaccinations, but it remains unclear, whether vaccination has an impact on the cytokine 
profile of IBD-patients, by which it may influence the process of the disease. 
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II. AIMS 
 
1.  To investigate the influence of bile acids on the ion-transporter activities of human 
colonic epithelial cells and to characterise the cellular pathomechanism of bile-induced 
diarrhoea. 
2.1.  To assess tumor necrosis factor-a (TNF-a), infliximab (IFX) concentrations, and 
antibodies against IFX in patients with inflammatory bowel disease (IBD) who develop loss 
of response, side effects, or allergic reaction during anti TNF-α therapy. 
2.2. To evaluate the cell-mediated immune response to split and whole virion influenza 
vaccines in patients with IBD treated with anti-TNF-α and/or immunosuppressive therapy. 
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III. MATERIALS AND METHODS  
 
1. The role of human colonic epithelial ion transporters in bile-acid induced diarrhoea 
1.1. Patients enrolled in the study 
Patients were divided into three groups. The first group contained patients having 
diarrhoea after ileum-resection/cholecystectomy (Diarrhoea). In the second group ileum-
resected/cholecystectomised patients were involved who did not develop diarrhoea (NON-
Diarrhoea). The control group included patients without any surgical intervention in the 
gastrointestinal tract. The patients enrolled in this study were between the age of 25-55 years. 
Informed consent was obtained prior to endoscopy. Protocols of the study were approved by 
the regional ethical committee at the University of Szeged, Szeged, Hungary. 3-6 colonic 
biopsies were obtained from the proximal colon (cecum, colon ascendens) from each patient 
undergoing colonoscopy at the First Department of Medicine. In none of the patients were 
macroscopic (by endoscopy) or microscopic (by histology) signs of the presence of 
inflammation in the colon. Patients with normal endoscopic findings were examined because 
of colorectal cancer screening or different abdominal complaints. 
1.2. Materials and solutions for the experiment 
 The compositions of the solutions used are shown in Table 1. The pH of HEPES-
buffered solutions was set to 7.4 with NaOH at 37oC. HCO3--buffered solutions were gassed 
with 95% O2/5% CO2 to set the pH to 7.4 at 37oC. 
General laboratory chemicals were obtained from Sigma-Aldrich. Collagenase A was 
obtained from Roche Diagnostic (Mannheim, Germany). HOE-642 (4-isopropyl-3-
methylsulphonylbenzoyl-guanidin methanesulphonate) was provided by Sanofi Aventis 
(Frankfurt, Germany) and was dissolved in dimethyl sulfoxide (DMSO). BCECF-AM (20,70-
biscarboxyethyl-5(6)-carboxyfluorescein-acetoxymethylester), FURA-2-AM (2-(6-
(bis(carboxymethyl)amino)-5-(2-(2-(bis(carboxymethyl)amino)-5-methylphenoxy)-ethoxy)-2-
benzofuranyl)-5-oxazolecarboxylic acetoxymethyl ester), BAPTA-AM (1,2-bis(o-
aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid), Magnesium-green-AM and TMRM 
(tetramethylrhodamine methyl ester) were obtained from Invitrogen (Eugene, OR); cell and 
tissue adhesive from Becton Dickinson Bioscience (Cell Tak, Bedford, MA). BCECF-AM, 
BAPTA-AM and TMRM were dissolved in DMSO, FURA-2-AM, and Magnesium-green-
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AM were dissolved in pluronic acid and DMSO. Thapsigargin was obtained from Merck 
(Darmstadt, Germany) and it was dissolved in DMSO. 
 
 
 
 
 
 
 
 
 
 
1.3. Isolation of colonic crypts 
Colonic crypts were isolated from three human biopsy specimens obtained from the 
proximal (cecum or colon ascendens) part of the large intestine. Only one segment of the 
colon was investigated in each patient. The tissue samples were placed immediately in ice-
cold NaHCO3 containing Hank’s balanced salt solution (HBSS). The samples were washed 
three times with HBSS, cut into small pieces with a razor blade and incubated in 1mM 
dithiothreitol (DTT) in HBSS for 15 minutes followed by 2x30 minutes enzymatic digestion 
with 0.38mg/mL collagenase A at 37oC and continuously gassed with 5% CO2/95% O2. The 
small fragments were mixed with a Pasteur pipette, the large fragments were allowed to settle 
down to the bottom of the flask under gravity for 35–40 seconds, and the supernatant removed 
and visualised under a Nikon stereo microscope (Jencons-PLS, Grinstead, UK). The crypts 
(200–300 crypts/isolation) were aspirated into a micropipette and transferred into a Petri dish. 
For fluorescent measurements the crypts were kept in a culture solution for 3 hours at 4oC 
before the experiments. The culture solution contained Dulbecco’s Modified Eagle’s Medium 
(DMEM), 10% fetal bovine serum (FBS; Sigma-Aldrich, Budapest, Hungary), 2mM L-
glutamine, 100U/mL penicillin, and 100µg streptomycin. An isolated colonic crypt is shown 
in Figure 1. 
Table 1. Composition of the solutions for in vitro studies. Values are concentrations in mmol/L 
  
Standard 
HEPES 
Ca2+ -free 
HEPES 
Na+ -free 
HEPES 
NH4Cl in 
HEPES 
Standard 
HCO3- 
Cl- -free 
HCO3- 
NaCl 130 130   110  115   
KCl 5 5 5   5 5   
MgCl2 1 1  1  1 1   
CaCl2 1    1  1 1   
Na-HEPES 10 10         
Glucose 10 10  10  10 10 10 
NaHCO3         25 25 
Na-gluconate           115 
Mg-gluconate           1 
Ca-gluconate           6 
K2-sulfate           2.5 
EGTA   0.1         
NH4Cl        20     
NMDG-Cl      140       
HEPES acid      10  10     
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1.4. Measurement of intracellular pH (pHi), Ca2+ concentration ([Ca2+]i) and ATP level 
(ATPi) by microfluorometry 
Colonic crypts were attached to 24mm glass coverslips covered with CellTak 3h after 
isolation and placed in a perfusion chamber mounted on the stage of an inverted fluorescent 
microscope linked to an excellence imaging system (Olympus, Budapest, Hungary). 
During the microfluorometry experiments, colonic crypts were incubated in standard 
HEPES solution at 37oC and loaded with the appropriate fluorescent dye. Crypts were 
continuously perfused with different solutions at a rate of 9-10ml/min. Two to three small 
areas (region of interest (ROIs)) from the surface of each crypt were investigated (Fig. 1). 
pHi was estimated with the pH-sensitive fluorescent dye BCECF-AM. After 
incubating with BCECF-AM (2µmol/l) for 20-30 minutes, colonic crypts were excited with 
light at wavelengths of 495nm and 440nm and the 495/440 fluorescence emission ratio were 
measured at 535nm [44, 45]. 
For the measurement of [Ca2+]i the cells were loaded with the Ca2+ sensitive 
fluorescent dye FURA-2-AM (5µmol/l) for 60 min. For excitation, 340 and 380nm filters 
were used, and the changes in [Ca2+]i were calculated from the fluorescence ratio (F340/F380) 
measured at 510nm. 
To determine changes of ATPi the fluorescent dye Mg-green-AM was used, which has 
been shown to indirectly reflect the changes in ATPi. Colonic crypts were incubated with Mg-
B 
M 
S 
L BL 
B. A. 
 
 
 
 
 
Figure 1. Phase contrast (A) and fluorescent (B) pictures of an isolated human colonic crypt. Crypts 
were fixed on glass coverglass. Three regions of interests (ROIs) of each crypt were excited with lights at 
different wavelengths and the fluorescence emissions were measured. B: base, M: middle, S: surface, L: 
lumen of the crypt, BL: basolateral membrane. 
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Green (4µmol/L) for 60 minutes than were excited with 476nm light and emission was 
detected at 500–550nm. Because ATP has a 10-fold greater affinity for Mg2+ than ADP, and 
most intracellular Mg2+ is present as Mg-ATP [46, 47], the ADP:ATP ratio can be monitored. 
The elevation of fluorescence intensity caused by the increase in free intracellular Mg2+ 
concentration suggests a reduction of ATPi [48]. The ATPi measurements were performed in 
standard HEPES-buffered solution. 
1.5. Determination of NHE activities 
During the measurement of pHi, in order to characterize NHE activity NH4Cl pulse 
technique was used in HEPES-buffered solution. Exposure of colonic crypts for 3 minutes to 
20mM NH4Cl induced an immediate rise in pHi due to the rapid entry of lipophilic base NH3 
into the cells. After the removal of NH4Cl, pHi rapidly decreased. This acidification is caused 
by the dissociation of intracellular NH4+ to H+ and NH3, followed by the diffusion of NH3 out 
of the cell. Under these conditions, the initial rate of pHi recovery from the acid load reflects 
the activities of NHEs. -J(B-) was calculated from the first 60 sec of pHi recovery from 
acidification. 
Further experiments were done to investigate the activities of the different NHE 
isoforms. The crypts were acid loaded by exposure to a 3-min-pulse of 20mM NH4Cl in 
HEPES solution followed by a 10-min-exposure of Na+-free HEPES solution. Due to the 
blocked acid/base transporters (neither sodium nor bicarbonate are present in the solution); 
the pHi is set to a stable acidic level. NHE activity was switched on by re-addition of 
extracellular sodium and the activities of NHEs were determined by measuring the initial rate 
of pHi recovery over the first 60 sec. The activities of the different NHE isoforms are 
extracted by using the isoform selective NHE inhibitor HOE-642. The isoform selectivity of 
HOE-642 is dose-dependent, 1µM HOE642 inhibits NHE1 whereas 50µM HOE642 inhibits 
both NHE1 and 2 but not NHE3 [49, 50]. The activities (A) of NHE isoforms can be 
calculated from the recoveries (R) as follows: 
ANHE1 = R0µM HOE-642 - R1µM HOE-642 
ANHE2 = R1µM HOE-642 - R50µM HOE-642 
ANHE3 = R50µM HOE-642 
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1.6. Measurement of CBE activity 
Cl- withdrawal technique was used to investigate the activity of CBE. Removing Cl- 
from the standard HCO3-/CO2 buffered solution caused alkalization due to the reversed 
activity of the Cl-/HCO3- exchanger. The activity of the exchanger was determined by 
measuring the initial rate of alkalization over the first 30 sec. 
1.7. Determination of buffering capacity and base efflux 
The total buffering capacity (βtotal) of colonic epithelial cells was estimated according 
to the NH4+ pre-pulse technique [51]. Colonic epithelial cells were exposed to various 
concentrations of NH4Cl in a Na+- and HCO3--free solution. βi (which refers to the ability of 
intrinsic cellular components to buffer changes of pHi) was estimated by the Henderson–
Hasselbach equation. βtotal was calculated from: βtotal = βi + βHCO3- = βi + 2.3x[HCO3-]i, where 
βHCO3- is the buffering capacity of the HCO3-/CO2 system. The measured rates of pHi change 
(dpH/dt) were converted to transmembrane base flux J(B-) using the equation: J(B-)=dpH/dtx 
βtotal. The βtotal value at the start point pHi was used for the calculation of J(B-). We denote 
base influx as J(B-) and base efflux (secretion) as -J(B-). 
1.8. Electron microscopy 
 Morphological changes of the different cell organelles of the colonic epithelial cells 
were evaluated by transmission electron microscopy (TEM). Biopsy samples were fixed in 
2% glutarldehyde (in PBS) overnight at 4°C degree. Samples were cut into small pieces (1X1 
mm) than were infiltrated with 2% gelatin (PBS) and the small cubes were made, which were 
than embedded to Embed 812 (EMS, USA) using a routine TEM embedding protocol. After 
the semithin sections (1µm), the thin (70nm) sections were cut for TEM examination. 
1.9. Measurement of mitochondrial transmembrane potential ( (∆ψ)m) 
Changes of (∆ψ)m were assessed by loading cells with 100nmol/L TMRM for 30 
minutes at 37°C to measure fluorescence in the perigranular mitochondrial region. 
Depolarisation of the mitochondria results in redistribution of TMRM from the mitochondria 
to the cytosol, causing a decrease in mitochondrial fluorescence [52]. Excitation 488nm, 
emission was detected at >550nm with Olympus Fluoview FV10i confocal system [48]. 
1.10. Statistical analysis 
 Values are means ± SE. Statistical analyses were performed using analysis of variance 
(ANOVA) with the post-hoc test Dunnett or Bonferroni. P≤0.05 was accepted as significant. 
 
22 
 
2. Biological therapy with anti-TNF-α IFX in the management of inflammatory bowel 
diseases (IBD)   
2.1. Study population I. 
In the first part of this prospective observational clinical study, 67 patients with CD 
and UC treated in our centre with IFX between 2011 and 2012 were enrolled and categorized 
into two groups. Blood samples of 36 patients with response loss, side effects, or 
hypersensitivity to IFX therapy (Group I) and 31 patients in complete clinical remission 
(Group Ⅱ) selected as a control group were collected to measure trough serum TNF-α level, 
IFX, and anti-IFX antibody (ATI) concentration. The study was approved by the Regional and 
Institutional Human Medical Biological Research Ethics Committee of the University of 
Szeged. The 3 infusion induction phase was followed by maintenance therapy in every 
patient. Data on patient demographics, clinical characteristics, concomitant corticosteroid and 
azathioprine therapies, need of surgery, C-reactive protein level, erythrocyte sedimentation 
rate (ESR), hematocrit, leukocyte and serum iron levels, and details on biological therapy 
were prospectively registered. Disease activity was measured by using the Crohn’s disease 
activity index (CDAI) [53] and partial Mayo score [54]. The patients’ demographic and 
clinical data are summarized in Table 2. We examined the correlation between loss of 
response, side effects, or hypersensitivity and serum TNF-α, IFX trough levels, and ATI 
concentrations. 
 
 
 
 
 
 
 
 
 Table 2. Demographic and clinical data of patients participating in the study. CD: Crohn’s disease; UC: 
Ulcerative colitis; IBD: Inflammatory bowel disease. 
Therapy IBD patients with 
loss of response, 
side effects, 
hypersensitivity 
(n=36) 
Control IBD 
patients 
(n=31) 
  
  
Mean age at diagnosis, yr 34.9 (17-67) 36.4 (17-66) 
Mean disease duration at biological therapy, yr 7.1 (1-20) 7.7 (1-21) 
CD/UC 19/17 17/14 
Male/Female 14/22 14/17 
Previous biological therapy 22 15 
Concominant steroid therapy 5 3 
Concominant thiopurine therapy 18 16 
Previous surgery 16 7 
Active disease 25 0 
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2.2. Study population II. 
The second section was a multicentre, prospective cohort study between September 
2012 and May 2013 at 4 Hungarian IBD centres (1st Department of Medicine, University of 
Szeged, 1st Department of Medicine, Semmelweis University, 2nd Department of Medicine, 
Semmelweis University, Military Hospital, Budapest). Patients with IBD were recruited 
during outpatient visits at the centres. Inclusion criteria included an age ≥ 18 years, diagnosis 
of IBD stable for more than 3 months, no signs of activity (biological and clinical) and not 
requiring any treatment modification for the disease at inclusion. Patients with active IBD 
were excluded. At inclusion, influenza vaccination was offered to every patient attending the 
involved centres. Patients were randomised to two groups on the basis of the acceptance of 
the vaccination. Patients refusing the vaccination served as control subjects. Patients and 
control subjects were followed up for 4 months to determine the clinical activity and the 
frequency of influenza infections. Clinical data included age at diagnosis, disease duration, 
gender, IBD phenotype according to the Montreal classification [53], types of concomitant 
therapies, and types and dosages of immunomodulator and biological therapy. Immunisation 
history for the previous 5 years was also obtained. 
Patients who received vaccination were divided into two further groups: patients 
treated with aminosalicylates without immunosuppressive therapy and patients treated with 
immunomodulator and/or biological therapy for at least three month before the vaccination. 
Control subjects had received maintenance therapy with immunomodulator and/or biological 
therapy for at least three month before the vaccination. 
The type of vaccine (whole virion or split virion vaccine) was randomly selected. 
Validated clinical activity indices – CDAI [54] and Partial Mayo Score (pMayo score) [55] 
were used for CD and UC to assess disease activity. The patients were scored and blood 
samples were also taken before and after the vaccination. The patients were contacted by 
phone every week for 16 weeks. During the phone calls, data from each patient were collected 
using a standardised questionnaire. The patients were asked about any change in clinical 
activity and the development of local and systemic adverse reactions. Ethical approvals for 
the study had been obtained from the Scientific and Research Ethics Committee of Hungary. 
Written informed consent was obtained from each subject. 
2.3. Vaccines 
Two non-live vaccines directed against the seasonal influenza virus 
A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010–like 
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B/Hubei-Wujiagang/158/2009 were used in the second part of the clinical study. Inactivated, 
split virion vaccine (IDFlu9) and inactivated, whole virion vaccine (Fluval AB) were 
administrated depending on a random selection.  
2.4. Measurement of serum IFX trough levels, and ATI concentrations, TNF-α, IFN-γ 
and IL-2 levels 
Enzyme-linked immunosorbent assay (ELISA) was applied to determine the serum 
levels of TNF-α, IFX trough levels, and ATI concentration. Blood samples, from IBD-
patients, participating in the first part of our clinical study, were obtained prior to application 
of IFX infusion. Q-INFLIXI ELISA, Q-ATI ELISA, and Q-TNF-α ELISA kits were obtained 
from Matriks Biotek, Ankara, Turkey. 
In the second part of our clinical study, serum was collected at baseline (pre-
vaccination) and 5 to 6 weeks after vaccination and it was stored at -20 oC until use. From the 
collected serum samples, we assessed cell-mediated immune response after vaccination and 
also compared it between patients treated with and without immunosuppressants. The cell-
mediated response to influenza A and B vaccines was evaluated using an INF-γ, IL-2, and 
TNF-α ELISA. Human TNF-α, IFN-γ and IL-2 ELISA kits were obtained from Life 
Technologies (Hungary). Serum was also obtained to assess leukocyte and lymphocyte levels 
quantitatively.  
2.5. Statistical analysis 
In order to examined the correlation between loss of response, the development of side 
effects or hypersensitivity, and serum TNF-α, IFX trough levels, and ATI concentrations, 
continuous data were analyzed using medians with an interquartile range (IQR). All 
categorical data were compared between groups of patients using the Pearson χ 2 statistic. 
Mann-Whitney U and Fisher’s exact tests were used for comparison of infliximab trough 
levels and ATIs in a subgroup of patients. Relation between laboratory parameters, IFX 
trough levels, and ATI was analyzed by Mann-Whitney U test. A P value less than 0.05 was 
considered to be significant. 
To the evaluation of cell-mediated immune response to the split and whole virion 
influenza vaccine in patients with IBD treated with anti-TNF-α and/or immunosuppressive 
therapy, data were analysed using SPSS version 21 software (SPSS, Chicago, IL). p<0.05 was 
considered significant. Categorical data were analysed using Pearson’s chi-square test and 
Fisher’s exact test. The effects of the vaccination on the antibody and cell-mediated immune 
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response were examined with multivariate analysis of variance (MANOVA) models with time 
as repeated measures (within-subject) factor and the types of the vaccines, the 
immunosuppressive status, the vaccinated status, the different therapies and the development 
of side-effects and influenza-like symptoms as between-subject factors. Pairwise comparisons 
were performed on estimated marginal means by considering the presence or absence of 
interaction; p-values were corrected with the Holm-Sidak method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
IV. RESULTS 
 
1. The role of human colonic epithelial ion transporters in bile-acid induced diarrhoea 
1.1. Chronic exposure of the colon to bile acids impair the activities of NHEs and CBE of 
isolated human colonic epithelial cells 
 Colonic crypts were isolated from patients whose colon is probably exposed to high 
concentrations of BA. Ileum-resected or cholecystectomised patients were divided into two 
groups depending on the presence (Diarrhoea; D) or absence (Non-Diarrhoea; NON-D) of 
diarrhoea after the surgical intervention. The calculated acid/base transporter activities were 
compared to those measured in control patients to determine the effects of BA on the 
epithelial ion transport.  
Representative curves of the pHi traces and the summary data of the calculated NHE 
activities are shown in Fig. 2A, B. The activities of the different NHE isoforms are extracted 
by using the isoform selective NHE inhibitor HOE-642. 1µM HOE642 inhibits NHE1 
whereas 50µM HOE642 inhibits both NHE1 and 2 but not NHE3 [49, 50]. The functions of 
all examined NHE isoforms were significantly reduced in patients in group D compared to 
control patients. 
The function of CBE was investigated using the Cl- withdrawal technique (Fig. 2C). 
Removal of Cl- from the standard HCO3-/CO2 bath solution caused a marked alkalization in 
colonic crypt cells suggesting the presence of a functionally active anion exchange 
mechanism. The activity of the CBE was significantly impaired in D group compared to 
control patients (Fig. 2D). In colonic crypt cells, isolated from NON-D patients, the activities 
of the examined acid/base transporters were not changed significantly, compared to the 
control group, suggesting the significant role of ion transporters in bile-induced diarrhoea. 
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1.2. Bile acid administration dose-dependently reduce the pHi of isolated human colonic 
epithelial cells 
Our next aim was to characterise the basic effects of BAs on healthy colonic epithelial 
cells. For these experiments, colonic crypts were isolated from control patients. The 
administration of the non-conjugated chenodeoxycholate (CDC) and the conjugated 
glycochenodeoxycholate (GCDC) dose-dependently reduced the pHi of perfused colonic 
epithelial cells (Fig 3). The characteristic response was a rapid decrease in pHi which than 
slowly recovered to a variable degree during continuous exposure to BAs (Fig 3A-D). In 
HEPES-buffered solution, the ∆pHmax was more prominent during CDC administration, 
compared to those observed in HCO3--containing solution, which can be explained by the 
increased buffering capacity of the colonic epithelial cells in the presence of HCO3-/CO2. 
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Figure 2. The activities of NHE and CBE were decreased in colonic epithelial cells isolated from ileum-
resected/cholecystectomised patients suffering from diarrhoea. (A) The activities of different NHE 
isoforms were determined by NH4Cl pulse technique with the isoform-specific NHE inhibitor HOE-642 as 
described in materials and methods. (B) Summary data of the calculated NHE activities. The activities of 
NHE1-3 were significantly impaired in patients suffering from diarrhoea. (C) Representative pHi traces 
showing the effect of the Cl- removal on the pHi of the colonic epithelial cells. (D) Summary data of the 
calculated CBE activities, which were significantly decreased in patients suffering from diarrhoea. Groups of 
patients were C: control patients; D: ileum-resected/cholecystectomised patients suffering from diarrhoea and 
NON-D: ileum-resected/cholecystectomised patients without diarrhoea. Data are presented as means ± SEM. 
n=5-6 patients/16-24 crypts/32-48 ROIs, *p<0.05 vs. control 
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The summary data of the calculated J(B-) in Fig 3E demonstrates that the influx of 
BAs was markedly greater when the non-conjugated CDC was administered compared to 
GCDC. This could be due to the lipophilic property of non-conjugated BAs which allows 
them to permeate through the membrane, while conjugated BAs need a BA transporter to 
enter the cells. 
 
 
 
 
 
 
 
 
 
 
  
 
 
1.3. High concentration of the non-conjugated CDC in a short term administration 
inhibits the activities of acid/base transporters of isolated human colonic epithelial cells 
Because impaired NHE and CBE activities were observed in patients suffering from 
diarrhoea, whose colon is probably continuously exposed to high concentration of BAs, we 
wanted to determine the influence of acute BA administration on the ion transport 
mechanisms of healthy human colonic epithelial cells. Colonic crypts isolated from control 
patients were used in these series of experiments. In order to investigate the effects of BAs on 
the activities of NHEs, we analysed the pHi recovery from an acid load induced by the 
removal of NH4Cl. The representative pHi traces (Fig 4A) and the summary data of the 
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Figure 3. Bile acids induce dose-dependent acidosis in isolated human colonic epithelial cells. 
Representative pHi traces (A-D) demonstrating the effect of non-conjugated CDC (0.1, 0.3 and 1 mM) and 
conjugated GCDC (0.1, 0.3 and 1 mM) administered in HEPES- (A, B) or HCO3-/CO2-buffered (C, D) 
solution. Summary data of the calculated base flux (J(B-/min)) (E) and the maximal pHi change (∆pHmax) (F) 
induced by bile acids. Data are presented as means ± SEM. n= 4-6 patients/14-18 crypts/28-36 ROIs. *p<0.05 
vs. CDC, #p<0.05 vs. HEPES. ND: not detectable. 
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calculated NHE activities (Fig 4B)  show that 10 min treatment with 0.1 mM CDC or GCDC 
had no effect on the functions of NHEs. Surprisingly, 0.3 mM GCDC significantly stimulated 
the activities of NHEs. When the colonic crypts were perfused with 0.3 mM CDC, an 
inhibition of the activities of NHEs was perceptible. To identify the exact NHE isoform, 
which is inhibited by 0.3 mM CDC, we used the ammonium pulse technique with the 
isoform-selective NHE inhibitor HOE-642 during the continuous perfusion with 0.3 mM 
CDC. According to our results, all of the NHE isoforms were significantly inhibited by 0.3 
mM CDC (Fig 4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
We also tested the effects of higher BA concentrations. When 20mM NH4Cl was 
applied at the same time with 1 mM CDC, the fluorescent intensities at 440 and 495 nm 
rapidly decreased causing an elevation of the 440/495 ratio. This must be due to the loss of 
BCECF and reflects the lysis of the cells. This harmful effect was absent when the crypts 
were exposed to 1 mM on the conjugated bile acid GCDC (data not shown). 
Figure 4. Administration of 0.3 mM CDC significantly inhibites NHE activity in isolated human colonic 
crypts. (A) Representative pHi curves showing the effects of CDC (0.1 and 0.3 mM) and GCDC (0.1 and 0.3 
mM) on the recovery from an acid load induced by removal of 20 mM NH4Cl. (B) Summary data of the initial 
rate of pHi recovery from acid load. (C) Summary data of the effect of 0.3 mM CDC on the calculated 
activities of the different NHE isoforms. The isoform-selective NHE inhibitor HOE-642 was administered as 
described in Matherials and Methods during treatment with 0.3 mM CDC. Data are presented as means ± 
SEM. n=3-6 patients/6-12 crypts/12-40 ROIs, *p<0.05 vs. control. 
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The Cl--withdrawal technique was applied to examine the activity of CBE as well. The 
apical Cl- removal from the extracellular solution increased the pHi of the cells by driving 
HCO3- into the cell via the apical CBE, whereas, re-addition of Cl- decreased pHi inducing 
secretion of HCO3- via the CBE. Treating the crypts with 0.3mM CDC resulted in a strong 
inhibition in the activity of CBE (Fig 5). Neither low concentration (0.1 mM) of CDC nor 0.1 
mM or 0.3 mM GCDC influenced the function of CBE. 
 
 
 
 
 
 
 
 
 
 
 
 
1.4. High concentration of the non-conjugated CDC induces severe mitochondrial 
damage 
 Our next aim was to explore the intracellular mechanisms by which BAs exert their 
inhibitory effect on acid/base transporters. Since previous works have reported that BAs can 
disrupt intracellular organelles (Golgi, mitochondria) [56-58], we firs analysed the structure of 
the cell compartments of human colonic epithelial cells following incubation with BAs. TEM 
(Fig 6) showed that low concentration of CDC (0.1 mM or 0.3 mM) or 1 mM GCDC for 1-10 
min had no effect on the structure of intracellular organelles. On the other hand, 10-minute 
exposure of the human colonic epithelial cells to high concentration (1 mM) of CDC strongly 
damaged all of the mitochondria. The mitochondria swelled up and the inner membrane 
 
Figure 5. 0.3 mM CDC significantly inhibites CBE activity in isolated human colonic crypts. (A) 
Representative pHi traces showing the effect of CDC (0.1 and 0.3 mM) and GCDC (0.1 and 0.3 mM) during 
removal of extracellular Cl-. (B) Summary data of the initial rate of pHi elevation after Cl- withdrawal. Data 
are presented as means ± SEM. n=3-6 patients/6-12 crypts/12-40 ROIs, *p<0.05 vs. control. 
31 
 
structures were disrupted. We did not observe such alteration in other intracellular organelles, 
such as endoplasmic reticulum, Golgi apparate or nuclei. For positive control experiments, the 
mitochondrial toxin carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 100 µM) was 
applied. The mitochondrial injury was similar to those seen after 1mM CDC treatment.  
 
 
 
 
 
 
 
 
1.5. Bile acid treatment decreases ATPi and (∆ψ)m of isolated human colonic epithelial 
cells 
 Since TEM experiments didn't reveal the inhibitory mechanism of 0.3 mM CDC 
completely, we tried to dissect the mechanism at a functional level. Therefore, in the next step 
we aimed to find out whether CDC has any influence on the ATPi level of the human colonic 
epithelial cells. Using the Mg-Green fluorescent probe, which is indirectly sensitive to ATPi 
(see Methods) we showed, that 0.3mM CDC significantly, but reversibly depleted ATPi of 
isolated human colonic epithelial cells (Fig. 7A, B). Following administration of 0.1mM CDC 
the ATPi was not affected (data not shown). In case of 1mM CDC, not only the structural 
impairment of the mitochondria was evident but a significant and irreversible decrease of the 
ATPi level was perceptible as well. For positive control, the mitochondrial toxin CCCP was 
applied similarly to the morphological studies. The fact that high concentration of CDC 
caused more prominent ATPi depletion than CCCP, suggests that BA have additional effects, 
which further decreases ATPi. To investigate the effects of BA on glicolytic ATP-production 
the combination of deoxyglucose (DOG)/idoacetamide (IAA) was used, which inhibit the 
glycolytic metabolism of colonic epithelial cells. 10mM DOG + 5mM IAA significantly and 
irreversibly depleted ATPi. CCCP and DOG+IAA together mimicked the effect of high 
conenctrations of CDC on the ATPi of isolated human colonic epithelial cells. 
Figure 6. Treatment with 0.3 mM CDC does not alter the structure of intracellular organelles. 
Transmission electron microscopy. Effects of CDC (0.3 mM and 1 mM) and GCDC (1 mM) on the 
mitochondria of human colonic epithelial cells. L: crypt lumen, arrow: mitochondria. 
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Alterations of (∆ψ)m were also examined. Representative traces in Fig. 7C 
demonstrate that administration of 0.1mM or 0.3mM CDC induced a significant decrease in 
TMRM fluorescence, which indicates the loss of (∆ψ)m. This effect was reversible, (∆ψ)m 
returned to basal level following removal of CDC. Furthermore 1mM CDC or 100µM CCCP 
caused a marked and irreversible reduction of (∆ψ)m. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6. CDC dose dependently increases [Ca2+]i via endoplasmic reticulum (ER) Ca2+ 
release and extracellular Ca2+ influx 
To further investigate the intracellular effects of BA, the changes of [Ca2+]i in isolated 
human colonic epithelial cells was measured during CDC-treatment. In our experiments, 
administration of CDC caused a dose-dependent increase in [Ca2+]i (Fig. 8A-C). The increase 
in [Ca2+]i was a sustained, plateau-like pathophysiological signal. The removal of Ca2+ from 
Figure 7. Treatment with 0.3 mM CDC significantly decreases ATPi and disturbs (∆ψ)m. (A) 
Representative curves of the Mg-green fluorescent experiments. Elevation of fluorescent intensity represents 
depletion in ATPi. (B) Summary data for the maximal fluorescent intensity changes. High concentrations of 
CDC significantly decreased ATPi. (C) Representative traces of the (∆ψ)m measurements. Decrease of 
fluorescent intensity represents loss of mitochondrial transmembrane potential. (D) Summary data for the 
maximal fluorescent intensity changes. High concentrations of CDC significantly decreased (∆ψ)m. All 
experiments were performed in HEPES-containing solution. Data are presented as means±SEM. n=3 
patients/5–6 crypts/13–15 ROIs. *p<0.05 vs. 1 mM CDC 
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the extracellular solution significantly decreased this effect. Pretreatment of the colonic crypts 
with BAPTA-AM (40µM), a fast chelator of [Ca2+]i abolished the effect of 0.1 and 0.3mM 
CDC, however, a moderate increase of [Ca2+]i was still observable when 1mM CDC was 
applied (Fig. 8D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We made attempts to identify the source of Ca2+, released during CDC-treatment. 
Caffeine (20mM) and/or Ruthenium red (RR, 10µM) were utilised in order to antagonise 
inositol triphosphate receptor (IP3R) and ryanodin receptor (RyR), which can mediate Ca2+ 
release from the ER. Representative curves and the summary bar chart (Fig. 9A, B) 
demonstrate that the application of caffeine significantly inhibited the increase in [Ca2+]i 
generated by 0.3mM CDC, while the administration of RR had no effect on the Ca2+ release. 
The rate of [Ca2+]i increase was significantly diminished as well during the administration of 
caffeine (Fig. 9C). 
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Figure 8. CDC dose-dependently induces an increase in the [Ca2+]i of isolated human colonic epithelial 
cells. (A-C) Representative curves showing the effect of CDC (0.1, 0.3 and 1 mM) on [Ca2+]i of isolated 
human colonic crypts in Ca2+-free or 1 mM Ca2+-containing solution with/without pretreatment with the 
[Ca2+]i  chelator BAPTA-AM. (D) Summary data for the maximal fluorescent intensity changes. All 
experiments were performed in HEPES-buffered solution. Data are presented as means ± SEM. n=2-4 
patients/5-10 crypts/10-21 ROIs. 
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In the next step gadolinium (Gd3+, 1µM) was applied to block plasma membrane Ca2+ 
entry channels. Gd3+ alone was not able to decrease the elevation of [Ca2+]i induced by 0.3mM 
CDC, while the simultaneous administration of Gd3+, caffeine and RR significantly reduced it 
(Fig. 10). 
 
 
 
 
 
Figure 9. CDC released Ca2+ from the ER in isolated human colonic epithelial cells. (A) Representative 
curves showing the effect of the IP3R inhibitor caffeine (20 mM), RyR inhibitor RR (10 µM) on the increase 
of [Ca2+]i induced by 0.3 mM CDC. (B) Summary data of the maximal fluorescent intensity changes. (C) 
Summary data of the calculated rate of [Ca2+]i increase. All experiment were performed in HEPES-buffered 
solution. Data are presented as means ± SEM. n=2-4 patients/5-8 crypts/10-18 ROIs. *p<0.05 vs. CDC in 0 
mM Ca2+ containing solution. 
Figure 10. CDC released Ca2+ from the ER and induced extracellular Ca2+ influx in isolated human 
colonic epithelial cells. (A) Representative curves showing the effect of the plasma membrane Ca2+ channel 
inhibitor Gd3+ (1 µM). (B) Summary data of the maximal fluorescent intensity changes. (C) Summary data of 
the calculated rate of [Ca2+]i increase. All experiment were performed in HEPES-buffered solution. Data are 
presented as means ± SEM. n=2-4 patients/5-8 crypts/10-18 ROIs. *p<0.05 vs. CDC 
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To further characterize the CDC-induced increase of [Ca2+]i in colonic epithelial cells, 
thapsigargin (Tg), the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA pump) 
inhibitor was applied. In Ca2+-free solution, Tg (2µM) induced Ca2+ store depletion with 
consequent [Ca2+]i elevation. This elevation was markedly decreased when Tg was 
administered after 0.3 mM CDC. Tg, when administered during 0.3mM CDC, further induced 
a slight increase in [Ca2+]i (Fig 11). These observations suggest that beside the extracellular 
Ca2+ influx, CDC deplete ER Ca2+-stores via IP3R mediated processes.  
 
 
 
 
 
 
 
 
 
 
 
1.7. The non-conjugated CDC induces ATP-dependent decrease in the Na+/H+-exchange 
activities and Ca2+-dependent inhibition of CBE activity in isolated human colonic 
epithelial cells 
Next we examined the potential connection between the intracellular effects of 0.3mM 
CDC (ATPi depletion and [Ca2+]i elevation) and the decreased function of acid/base 
transporters following treatment with the BA. Ammonium pulse technique (Fig. 12A) showed 
that chelation of intracellular Ca2+ with BAPTA-AM did not influence the inhibitory effect of 
0.3mM CDC on the NHE activity. In contrast, when the glycolysis inhitbitors DOG+IAA 
were applied the same inhibition of NHEs was perceptible (Fig. 11B), which suggests that 
CDC inhibits NHE via ATPi-depletion. This result confirms the observation of other 
Figure 11. The ER Ca2+ pump SERCA inhibitor further increases [Ca2+]i after CDC treatment in 
isolated human colonic crypts. (A) Representative traces showing the effects of SERCA-inhibitor Tg (2 µM) 
administered alone, following or during 0.3 mM CDC on the [Ca2+]i. (B) Summary data of the maximal 
fluorescent intensity changes and (C) the calculated rate of [Ca2+]i increase. All experiments were performed 
in Ca2+-free HEPES-buffered solution. Data are presented as means ± SEM. n=2-3 patients/5-6 crypts/12-14 
ROIs. #p<0.05, ##p<0.01 vs. Tg alone. 
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workgroups that NHEs are secondary-active transporters and their function is ATP-dependent 
[59-61]. 
 
 
 
 
We also investigated the inhibitory effect of 0.3mM CDC on CBE more detailed. We 
tested the effects of [Ca2+]i chelation and ATPi depletion during the Cl--removal technique in 
isolated human colonic epithelial cells. In our experiments, the intracellular Ca2+-chelator 
BAPTA-AM completely abolished the inhibitory effect of 0.3mM CDC on the activity of 
CBE. In contrast, depletion of ATPi with DOG+IAA was not able to reduce CBE activity. 
These results provide evidence for the strong Ca2+-dependence of the transporter. Our 
observations suggest that bile acids inhibit CBE activity via toxic [Ca2+]i elevation unlike 
NHE activity, which is inhibited by ATPi depletion (Fig. 13). 
 
 
 
 
Figure 12. 0.3 mM CDC induced ATPi-dependent inhibition of NHEs in isolated human colonic 
epithelial cells. (A) Representative pHi curves showing the effect of 0.3 mM CDC, (ATP)i depletion or 
pretreatment with the [Ca2+]i chelator BAPTA-AM on the initial rate of pHi recovery from an acid load 
induced by the removal of 20 mM NH4Cl. (B) Summary data of the initial rate of pHi recovery from an acid 
load. The depletion of ATPi, mimicked, but the prevention of Ca2+ elevation did not change the effect of CDC 
on the NHE activities. The experiments were performed in HEPES-containing solution. Data are presented as 
means ± SEM. n=3-6 patients/5-12 crypts/8-40 ROIs. *p<0.05 vs. control. 
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2. Biological therapy with the anti-TNF-α IFX in the management of IBD 
2.1. Assessment of TNF-α, IFX concentrations, and antibodies against IFX molecules in 
IBD-patients who develop loss of response, side effects, or allergic reaction during anti 
TNF-a therapy 
The median CDAI in groups Ⅰ and Ⅱ were 138 (IQR 68-186) and 50 (IQR 34-70), 
respectively; the partial Mayo score in the two groups were 5 (IQR 3-6) and 1 (IQR 0-1), 
respectively. The median serum TNF-α levels were 10.5 (IQR 3.2-18-9) and 6.3 (IQR 1.5-
15.7) pg/mL in groups Ⅰ and Ⅱ, respectively. The median IFX trough level was 3.1 (IQR 
2.6-5.04) and 3.5 (IQR 2.6-4.7) µg/mL in the two groups, respectively. Fourteen patients were 
found to have ATI positivity with a median of 933 µg/mL (IQR 328-3306). ROC analysis 
revealed that the cut off value of serum IFX for detecting ATI was 3.01 µg/mL. The serum 
TNF-α level was significantly higher in the presence of ATI (24.23 pg/mL vs 6.28 pg/mL, P= 
0.005). ATI positivity correlated significantly with low trough levels of IFX (2.66 µg/mL vs 
3.86 µg/mL, P = 0.015). However, no difference was detected in serum IFX and antibody 
Figure 13. 0.3 mM CDC induced ATPi-dependent inhibition of NHEs and Ca2+-dependent decrease in the 
activity of CBE in isolated human colonic epithelial cells. (A) Representative pHi curves demonstrating the 
effect of 0.3 mM CDC, ATPi depletion or pretreatment with the [Ca2+]i chelator BAPTA-AM on the removal of 
extracellular Cl−. (B) Summary data of the initial rate of pHi elevation after Cl− withdrawal. The chelation of the 
[Ca2+]i elevation abolished the inhibitory effect of CDC. The experiments were performed in HCO3−-containing 
solution. Data are presented as means±SEM. n=3–6 patients/5–12 crypts/8–40 ROIs. *p<0.05 vs. Control. 
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levels between the two groups (2.67 µg/mL vs 2.66 µg/mL, P = 0.821). Serum IFX and ATI 
levels in patients with ATI positivity are summarized in Table 3. 
Two of the IBD patients with antibodies against anti TNF-α developed side effects, 5 
patients lost response, and an allergic reaction occurred in 3 patients. 37 patients were 
previously treated with biologicals, with development of ATI being more frequent those 
patients (P = 0.048). Dose intensification was required in 9 patients. No association was 
found between dose intensification and the development of ATI. Concomitant 
immunosuppression had no impact on IFX trough levels or on the development of ATI 
formation. Increased ESR and C-reactive protein correlated significantly with lower serum 
IFX level (P = 0.04 and P = 0.002). The serum TNF-α level was higher in patients not treated 
concomitantly with steroids (P = 0.038). 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. The impact of influenza-vaccination on the cellular immune response of IBD-
patients treated with anti-TNF-α and/or immunosuppressive therapy. 
209 IBD patients (127 with CD, 82 with UC) were eligible and enrolled in the study. 
156 patients received influenza vaccination, whereas 53 patients (control group) refused the 
Patients Serum IFX 
level (µg/ml) 
ATI level 
(µg/ml) 
1 2.75 3194.90 
2 2.68 258.55 
3 2.67 1056.25 
4 2.66 3055.04 
5 2.93 3712.82 
6 2.26 3343.07 
7 2.66 129.54 
8 2.49 4540.33 
9 12.4 58.92 
10 2.66 3679.21 
11 2.65 536.57 
12 1.90 555.53 
13 1.71 810.87 
14 4.67 46.34 
Table 3. Serum IFX and ATI levels in case of ATI positivity 
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vaccine – the acceptance rate of vaccination was 66.3%. Whole virion vaccine was given to 
57; split virion vaccine was given to 99 patients. The mean age of the vaccinated patients was 
27.9 years; 84 were women, 72 were men. In the control group, the mean age was 30.7 years, 
29 were women, 24 were men. Out of the 156 vaccinated patients, 98 had CD, 58 had UC. 
Median disease duration was 9 years for CD (IQR 5-13), and 9 years for UC (IQR 4-15.8). Of 
the control subjects, 29 had CD and 24 had UC. Median disease duration was 7 years for both 
CD (IQR 5-14) and UC (IQR 4.5-12). 
Out of the 156 vaccinated patients, 115 received immunosuppressive therapy. The non 
immunosuppressive group of vaccinated subjects was composed of 41 patients. Out of the 53 
control subjects, 32 received immunosuppressive therapy. Twenty-one patients were free of 
immunosuppressive therapy. 8.3% of the patients were regularly vaccinated against seasonal 
influenza virus. 39 patients (21.5%) had received the last vaccination within one year, 25 
patients (13.8%) within 3 years and 3 patients (1.7%) within 5 years. 63% of the patients had 
received the last vaccination more than 5 years earlier. Demographic and clinical 
characteristics, disease activity at the time of the vaccination and treatment types are 
summarised in Table 4. 
Leukocyte and lymphocyte levels varied between 2.78-17.6 G/L and 0.38-20.9 G/L 
before and between 2.41-20.54 G/L and 7.9-43.8 G/L after the vaccination. Leukocyte and 
lymphocyte levels did not differ significantly after vaccination. The level of INF-γ varied 
between 9.9 and 39.1 pg/ml before and between 11.7 and 39.1 pg/ml after vaccination. IL-2 
levels varied between 14.7 and 152.6 pg/ml before and between 13.8 and 152.3 pg/ml after 
the vaccination. The levels of TNF-α varied as: 11.6-360.4 pg/ml before and 8.5-216.9 pg/ml 
after the administration of the vaccine. Neither TNF-α, nor INF-γ levels changed significantly 
after influenza vaccination; however, a significant decrease was observed in the level of IL-2 
after vaccination with split vs. whole virion vaccine (p=0.004).  
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Table 4. Demographic, clinical characteristics, disease activities and treatment types of patients, enrolled in the 
study. 
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V. DISCUSSION 
 
1. The role of human colonic epithelial ion transporters in bile-acid induced diarrhoea 
One of the main non-motor functions of the colon is to absorb about 90% of the fluid 
(~1.5 to 1.9 liters), arriving daily from the small intestine [62]. This great absorptive capacity 
of the large intestine is mediated by the polarised epithelial cell layer which maintains the 
balance between absorption and secretion. These polarised epithelial cells are equipped with 
numerous ion channels, pumps and carriers located either on the luminal or basolateral 
membrane, allowing highly efficient transport of large amount of water and salts, especially 
Na+ and Cl-  [63]. The electroneutral NaCl absorption is probably mediated via the coupled 
activity of Na+/H+ exchangers and Cl-/HCO3- exchangers [2, 3]. The fact that impaired 
activities of these transporters were observed in diarrhoea-associated diseases, such as 
ulcerative colitis and secretory diarrhoea [12, 13, 64], underlies their importance in colonic 
electrolyte and water absorption. 
BAs are amphipathic molecules aiding fat solubilisation and lipid digestion in the 
intestine. Besides the physiological functions, BAs are also known to induce diarrhoea, a 
common feature of BA malabsorption. BAM often develops after small bowel resection or 
post-cholecystectomy [14-17]. Increased colonic motility [65], stimulated defecation, mucosal 
damage, increased epithelial permeability and stimulated mucus secretion [66] are the major 
responses to the elevated amount of BAs in the colon . In addition, the influence of BAs on 
the secretory function of colonic epithelium is supposed to be critical in the development of 
bile-induced diarrhoea. Confirming this, the prosecretory action of BAs on colonic epithelial 
cells was demonstrated [21-23, 67, 68]. Although bile-induced diarrhoea is a frequent 
complication affecting high number of patients, its pathogenesis is not yet completely 
understood. 
Because BAs can induce diarrhoea when they are present in the colon at high 
concentration, in our first series of experiments, we wished to clarify whether the decreased 
activities of acid/base transporters are involved in this process. Thus, we isolated colonic 
crypts from patients, whose colon is probably continuously exposed to high concentration of 
BAs. Ileum-resected or cholecystectomised patients were involved in the study and were 
divided into two groups depending on having (Diarrhoea - D) or not having diarrhoea (Non-
Diarrhoea – NON-D) after the surgical intervention. In the D-group, the activities of all 
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examined NHE isoforms were markedly lower than in control patients. Next, we tested 
whether the activity of the CBE is also influenced by chronic BA exposure. Similarly to 
NHEs, the activity of the CBE was significantly diminished in D-patients compared to 
controls. It is important to note that the functions of the examined acid/base transporters were 
unaltered in colonic epithelial cells isolated from biopsy samples of NON-D patients. These 
data suggest that the reduced absorptive function of the colon is probably due to the 
continuous presence of non-physiological concentration of BAs. This is in agreement with the 
observation that CDC reverses the absorption of water and Na+ into secretion in rat colon 
[69], moreover, Freel et al. showed inhibited Na+ absorption in rabbit colon induced by BAs 
[70]. In a more previous study Binder et al. also reported that excess BAs in rat colon 
decrease Na+ and Cl- absorption [71]. 
Following our first fundamental observation regarding the long-term influence of BAs, 
we aimed to characterise their basic effects on human colonic epithelial cells. Thus, colonic 
crypts isolated from control patients were treated with the non-conjugated BA CDC and the 
conjugated GCDC. We used conjugated and non-conjugated BAs as well, because due to the 
conjugation, the natures of the BAs are changing. Being a weak acid, CDC can traverse cell 
membrane by passive diffusion [72]. On the contrary, conjugated BAs are water soluble and 
require active transport mechanisms for cellular uptake [73]. Indeed, the presence of the 
apical sodium dependent BA transporter ASBT was found to be expressed in human biopsies 
from different segments of the large intestine [74]. In this study, three concentrations of the 
BAs were applied: 0.1 mM as a low, while 0.3 and 1 mM served as high concentrations, in 
order to imitate physiological and non-physiological circumstances. This was based on the 
data of Hamilton et al., that the physiological concentration of total BAs – including 
conjugated and non-conjugated forms - in the proximal colon (cecum) reaches 1 mM [75]. 
Moreover, in the large intestine, BAs are metabolized, mainly deconjugated, by resident 
bacteria [76-78], leading to the elevated formation of the more lipohil non-conjugated BAs. In 
our experiments, administration of BAs caused an immediate, dose-dependent and reversible 
decrease of the pHi, which acidosis was more prominent in case of the CDC, due to the 
typical characteristics of the non-conjugated BAs. 
Because decreased activities of NHEs and CBE were observed in patients suffering 
from diarrhoea, whose colon is probably continuously exposed to high concentration of BAs, 
next we investigated the short-term effects of BAs on the functions of ion transporters of 
colonic epithelial cells. Colonic crypts, isolated from control patients, were treated with 0.1 or 
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0.3 mM CDC or GCDC. Administration of CDC in a relative high concentration (0.3 mM) 
resulted in a significant inhibition of NHEs and CBE of human colonic epithelial cells, 
suggesting the possible toxic effects of high doses of non-conjugated BAs. In order to identify 
the exact NHE isoform, which is inhibited by 0.3 mM CDC, the isoform-specific NHE 
inhibitor HOE-642 was applied. Our experiments showed that the functions of all examined 
NHE isoforms were reduced in response to 0.3 mM CDC. Although the secretion of Cl- and 
Na+ in response to BAs was not investigated in this study, it is already well established that 
BAs stimulate intestinal electrolyte and fluid secretion [24] and the decreased absorption and 
elevated secretion of ions may account for the diarrhoea associated with BAM. Surprisingly, 
0.3 mM GCDC markedly stimulated the activities of NHEs. Physiologically, most of the BAs 
are present in conjugated form, which protects the tissues from the strongly detergent non-
conjugated BAs. 
Having seen that both acute and chronic exposure of the colonic epithelial cells to BAs 
resulted in reduced electrolyte absorptive processes, the question raised how BAs are able to 
explain this inhibitory effect and what is the molecular background of this inhibition. First, we 
investigated the effects of BAs on the morphology of intracellular organelles, as a potent 
candidate for the target of Bas. Basing this idea on previous studies, demonstrating that BAs 
can perturb intracellular organelles and induce Golgi fragmentation, ER-stress and disruption 
of the mitochondria not only in cultured colonic epithelial cells but also in pancreatic ductal 
cells [56-58]. In our experiments, 10-minute exposure of the colonic epithelial cells to 0.3 
mM CDC or 1 mM GCDC did not induce any visible alteration in the morphology of the cell 
compartments. Nevertheless, 1 mM CDC caused a severe damage in all of the mitochondria. 
The mitochondria swelled up and the structure of the inner membranes was lost, whereas 
other intracellular organelles seemed to remain intact. For positive control experiments, the 
mitochondrial uncoupling toxin CCCP (100 µM) was used, which resulted in the same 
mitochondrial injury as it was observed after treatment with 1 mM CDC. 
Although 0.3 mM CDC inhibited the activities of acid/base transporters, but it did not 
induce alteration in the structure of intracellular organelles, next we investigated whether 
ATPi is affected by 0.3 mM CDC. Administration of 0.3 mM CDC significantly but 
reversibly depleted the ATPi of isolated human colonic epithelial cells. In addition, 1 mM 
CDC caused a more prominent reduction in ATPi level. Exposure of the isolated colonic 
epithelial cells to the glycolysis inhibitors 10 mM DOG + 5 mM IAA together with the 
mitochondrial uncoupler toxin CCCP mimicked the effect of 1 mM CDC. These observations 
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indicate that non-conjugated BAs in high concentration inhibit both the oxidative and the 
glycolytic metabolism of the colonic epithelial cells. 
In order to more profoundly examine the influence of CDC on the processes 
concerning the mitochondrial metabolism of the isolated human colonic epithelial cells, we 
decided to investigate mitochondrial transmembrane potential (∆ψ)m, being the essential 
driving force for ATP synthesis. 0.1 mM and 0.3 mM CDC induced a marked reduction of 
TMRM fluorescence, which indicates the loss of ∆ψm. This effect was reversible, ∆ψm 
returned to basal level following removal of the BA. The significant and irreversible reduction 
of ∆ψm caused by 1 mM CDC was more prominent than it was observed after the 
administration of the mitochondrial uncoupler toxin CCCP. Taken together, these data clearly 
demonstrate that 0.3 mM CDC is not enough to cause structural damage of the cell 
compartments but it is still able to deplete ATPi and diminish ∆ψm by which perturbs the 
energy homeostasis of human colonic epithelial cells. These processes may play a role in the 
impaired function of ion absorption. 
Next, we investigated another potential intracellular target of BAs, the Ca2+ 
signalisation, a well-known mediator of numerous cellular processes. It was shown previously 
that the Cl-/HCO3- exchanger DRA and NHE3 are inhibited by the pathological increase of 
intracellular Ca2+ [50, 79]. In our experiments, CDC dose-dependently induced an increase of 
[Ca2+]i, which was a sustained non-physiological elevation with a plateau-characteristic. The 
removal of Ca2+ from the extracellular solution mostly prevented, while pretreatment of the 
colonic crypts with BAPTA-AM (40 µM), a chelator of Ca2+i almost completely abolished the 
effect of 0.3 mM CDC. When elevation of [Ca2+]i occurs, the source of Ca2+ could be the ER 
or the extracellular space. From the ER, Ca2+ enters into the cytoplasm through IP3R and/or 
RyR. In order to identify the orignin of elevated Ca2+ during administration of 0.3 mM CDC, 
the IP3R antagonist caffeine, the RyR-blocker RR and the plasma membrane Ca2+ channel 
inhibitor gadolinium (Gd3+) were applied. In our experiments, caffeine, but not RR or Gd3+, 
reduced the [Ca2+]i elevation, induced by 0.3 mM CDC. The fact that neither RR, nor Gd3+ 
alone were able to prevent the toxic Ca2+ signal, suggests that CDC mobilizes stored Ca2+ 
from the ER via IP3R. However, since the inhibition of IP3R did not completely abolished the 
effect of CDC, proposes that extracellular Ca2+ influx must be a key player as well. This 
process is most probably mediated by Gd3+ insensitive Ca2+ channels or Na+/Ca2+ exchangers 
(NCXs). Moreover, the non-specific cation channels can also not be excluded. These ion 
channels have large Na+, Ca2+ and/or K+ conductance but since specific inhibitors are lacking, 
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it is difficult to distinguish their functions. Beside, the SERCA inhibitor thapsigargin induced 
a further elevation of the [Ca2+]i after or during CDC administration suggests that CDC does 
not completely empty the ER Ca2+ store. These observations lead us to the hypothesis that 
CDC mobilizes stored Ca2+ from the ER and promotes the influx of external Ca2+. The 
increase in [Ca2+]i in response to CDC is probably not due to the detergent property of the 
BA, because this effect is reversible. Nevertheless, the involvement of other minor 
intracellular Ca2+ stores (mitochondria, Golgi, peroxysomes) must also be considered as a 
potential target of CDC in the colonic epithelial cells. 
Finally, we examined whether there is a conjunction between the inhibitory effect of 
0.3 mM CDC on the activities of acid/base transporters and its intracellular actions on ATPi or 
[Ca2+]i. Therefore, we measured again the ion transporter activities of human colonic crypts, 
isolated from patients with healthy colon. Depletion of ATPi with the glycolysis inhibitors 
DOG+IAA resulted in a similar decrease of the activities of NHEs as it was perceptible 
following administration of 0.3 mM CDC. In contrast, pretreatment of the colonic epithelial 
cells with the Ca2+i chelator BAPTA-AM did not prevent the toxic effect of 0.3 mM CDC on 
the activities of NHEs. These results indicate that 0.3 mM CDC inhibits the functions of 
NHEs via depleting ATPi. Elevation of [Ca2+]i may play a minor role in this process. This is in 
agreement with previous observations that NHEs are secondary-active transporters and their 
function is ATP-dependent [59-61]. Still, the consequences of ATPi depletion and the role of 
[Ca2+]i increase cannot be completely distinguished from each other, since CDC affects them 
simultaneously. Beside the Na+ transport, the Cl- absorptive capacity via the CBE of the 
colonic epithelial cells was also tested again. ATPi depletion caused by the glycolysis 
inhibitors did not have any influence on the activity of CBE. However, preincubation of the 
colonic crypts with the Ca2+i chelator BAPTA-AM, which almost completely abolished the 
sustained elevation of [Ca2+]i induced by 0.3 mM CDC, restored the decreased activity of 
CBE due to 0.3 mM CDC. This observation further supports the hypothesis that CBE is 
inhibited by the non-physiological elevation of [Ca2+]i [79]. 
In conclusion, in this study we provided evidence that BAs impair the ion transport 
mechanisms of human colonic epithelial cells which could play an important role in the 
development of BAM associated diarrhoea. We demonstrated that chronic exposure of the 
colon to high concentration of bile acids results in decreased activities of acid/base 
transporters, responsible for NaCl absorption. In addition, the non-conjugated BA 
chenodeoxycholate inhibits the activities of NHEs and CBE of isolated human colonic 
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epithelial cells by depleting ATPi and inducing toxic sustained intracellular Ca2+-elevation. 
These processes may reduce fluid and electrolyte absorption in the colon and generate 
diarrhoea. Thus, our results might contribute to the development of new therapeutical 
approaches in the treatment of bile-induced diarrhoea. 
 
2. Biological therapy with the anti-TNF-α IFX in the management of IBD 
In the past decades, biological therapy revolutionized the treatment of IBD. At the 
beginning, it was introduced into the medication of those patients, who have failed 
conventional therapies. Unfortunately, a significant proportion of patients loses response to 
these agents or develops adverse effects, such as infusion- or hypersensitive reaction during 
the course of the treatment. Nowadays, clinicians are willing to start biological therapy 
sooner, parallel with steroids and/or immunomodulators, in order to avoid unfavourable 
outcomes. The prevention and the management of therapeutic failure with IFX is a significant 
challenge for clinicians in the field of IBD. Loss of response occurs mostly due to the 
phenomenon of immunogenicity, the production of neutralizing anti-drug antibodies, that 
accelerates drug clearance leading to subtherapeutic drug concentrations [80]. 
Immunogenicity induced by IFX can be determined by monitoring the serum concentrations 
of ATI, TNF-α and IFX [81]. It has been repeatedly demonstrated, that the formation of ATIs 
results in a decreased level of serum IFX, increased risk of infusion reactions and diminished 
clinical response [82, 83]. Maintenance vs. episodical IFX therapy or concomitant 
immunomodulators are proven to be benefical therapeutical strategies that reduce ATI 
development and the risk of infusion reactions [84, 85]. Interestingly, antibodies against IFX 
Fab fragment are detectable in patients never received IFX therapy, they may be present 
before IFX treatment in patients naive to biological agents, and may predict long-term clinical 
efficacy and safety of IFX in CD and UC. Measurement of these antibodies before initiation 
of IFX treatment might help clinicians to select the best type of therapeutic TNF-blocker in 
individual patients [86].  
In our study both increased TNF-α and decreased IFX levels correlated with the 
presence of ATI, although neither ATI nor serum IFX influenced the outcome of the therapy. 
A meta-analysis also concluded that the presence of ATIs is associated with a significantly 
higher risk of loss of clinical response to IFX and lower serum IFX levels in patients with 
IBD [87]. Although these statements and consequences are logical, the results of the clinical 
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practice are confusing. In a prospective cohort study Steenholdt et al. found that improved 
clinical outcome was associated with a higher increase in IFX levels [88]. Moreover, in a 
systematic review Chaparro published that there is a close relationship between trough levels 
of anti-TNF-α and maintenance of response [39]. Although higher serum IFX level proved to 
predict longer duration of response and clinical remission by some studies both in CD and UC 
[85, 87, 89, 90], a Japanese study showed that the median trough levels of IFX did not differ 
significantly in patients who maintained and who lost response to IFX [91]. In the study of 
Bortlik et al. the median trough levels of IFX were significantly higher and antibody titers 
were significantly lower in patients with concomitant thiopurines [92]. In our study, previous 
biological therapy had more significant effect on the outcome of IFX therapy than the 
concomitant use of thiopurines. According to the study of Afif et al., dose escalation was 
associated with a high clinical response in patients with subtherapeutical IFX levels and 
negative ATI, and better clinical outcome was achieved in ATI positive patients switching to 
another anti-TNF-α-drug  [93]. On the basis of previous studies, concomitant corticosteroid 
therapy is suggested to decrease the effect of TNF-α blocker confirmed by our results 
regarding the higher TNF-α level in patients receiving steroids [94, 95]. 
Because of these controversial data, the usefulness of monitoring the trough levels and 
ATI concentrations in the therapeutic decisions may be questionable. Our results do not 
confirm the clinical utility of trough level and antibody measurement in the differentiation of 
“problematic’ patients with loss of response of adverse reactions vs. those who respond 
appropriately to the biological therapy. The reason of the conflicting outcomes of the studies 
could be due to the differences in patient selection, type of analysis, the large interindividual 
dissimilarities in the reactions for the treatment or the lack of uniform reporting, which makes 
difficult to understand the results and to compare the individual studies. Anyway, therapeutic 
drug monitoring could be a key device in the optimised management of IBD patients, 
however, the methods should be correctly standardised. Steenholdt et al. underlines the 
importance of individualised therapy, which provides cost-effectiveness as an extra 
advantage, without any apparent negative effect on clinical efficacy [96]. The same goals has 
the Trough level Adapted infliXImab Treatment (TAXIT) trial, which was performed in order 
to investigate the value of individualised treatment with IFX based on therapeutic drug 
monitoring. Furthermore, Vande Casteele et al. revealed, that IFX-dosing based on 
therapeutic drug monitoring was associated with fewer flares during the course of treatment, 
in comparison with clinically based drug-dosing [97].  
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In conclusion, in our prospective observational study we found significant association 
between serum TNF-α level and the presence of ATI; and also between ATI positivity and 
low trough levels of IFX.  However, antibody positivity and lower serum IFX levels did not 
correlate with loss of response, side-effects and hypersensitivity. Previous use of IFX 
correlated with the development of ATI. When previous studies determined only ATI 
positivity or negativity, detectable IFX serum concentration suggested many fals-negative 
results. This factor was decreased by the quantification of ATI titers in our study. On the basis 
of the present work, we suggest that further prospective studies are needed to determine 
whether the simultaneous measurement of serum TNF-α level, serum anti TNF-α 
concentration and antibodies against anti TNF-α may help to optimize the therapy in the 
critical situations. 
Patients on immunosuppression or biological therapy are supposed to be at increased 
risk of influenza, since immunotherapy is known to predominantly impair cellular immunity, 
leaving the humoral immune response more or less intact [98]. Thus, annual influenza 
vaccination is recommended for all patients with IBD on immunomodulators. In the second 
part of our study, we examined whether influenza vaccination has an effect on the cell-
mediated immune response by measuring the pre- and post-immunisation levels of INF-γ, IL-
2 and TNF-α. Interestingly, only the level of IL-2 decreased significantly after vaccination. 
The study by Holvast et al. assessed cell-mediated responses to influenza vaccination in 
patients with SLE. They found that the frequencies of CD4+ T cells producing TNF and IL-2 
were lower in patients after vaccination compared with healthy control subjects. They also 
found that this diminished cell-mediated response may reflect the effects of concomitant use 
of immunosuppressive drugs [99]. The study of Long et al. also found a diminished humoral 
and cell-mediated immune response to monovalent 2009 pandemic influenza A (H1N1/2009) 
and seasonal trivalent influenza vaccines in subjects with SLE but not with sickle cell disease 
or asthma, presumably due to the different immunocompromised status of these children 
[100]. Our results suggest that IBD patients on immunosuppressive therapy are recommended 
to be immunised against influenza, but larger and more detailed studies are needed to examine 
the cell-mediated response and to determine the efficacy of influenza vaccination in 
immunocompromised IBD-patients. 
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